Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) Operating Income (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Operating Income readings, the most recent being -$4.2 million for Q3 2025.

  • Quarterly Operating Income fell 52.97% to -$4.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$19.6 million through Sep 2025, down 81.97% year-over-year, with the annual reading at -$16.0 million for FY2024, 71.66% down from the prior year.
  • Operating Income hit -$4.2 million in Q3 2025 for Greenwich LifeSciences, down from -$4.0 million in the prior quarter.
  • Across five years, Operating Income topped out at -$600606.0 in Q1 2021 and bottomed at -$8.1 million in Q4 2024.
  • Average Operating Income over 5 years is -$2.6 million, with a median of -$2.5 million recorded in 2023.
  • The largest annual shift saw Operating Income tumbled 258.05% in 2021 before it grew 2.03% in 2023.
  • Greenwich LifeSciences' Operating Income stood at -$2.4 million in 2021, then fell by 21.77% to -$2.9 million in 2022, then rose by 2.03% to -$2.8 million in 2023, then crashed by 185.05% to -$8.1 million in 2024, then soared by 48.36% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Operating Income are -$4.2 million (Q3 2025), -$4.0 million (Q2 2025), and -$3.3 million (Q1 2025).